Site-avoidance mechanism Doxorubicin andamphotericin B 5. Site-specific targeting Anti-inflammatory drugs, anti-cancer, anti-infection 6. Improved transfer of hydrophilic, charged molecules Antibiotics, chelators, plasmids, and genes 7. Improved penetration into tissues Corticosteroids, anesthetics, and insulin Liposomes in parasitic diseases and infections From the time when conventional liposomes are digested by phagocytic cells in the body after intravenous management, they are ideal vehicles for the targeting drug molecules into these macrophages.

The best known instances of this ‘Trojan horse-like’ mechanism are several parasitic diseases which normally exist in the cell of MPS. They comprise leishmaniasis and several fungal infections. Leishmaniasis is a parasitic infection of macrophages which affects over 100 million people in tropical regions and is often deadly. The effectual dose of drugs, mostly different antimonials, Navitoclax solubility dmso is not much lower than the toxic one. Liposomes Everolimus accumulate in the very same cell population which is infected,

and so an ideal drug delivery vehicle was proposed [52]. Certainly, the therapeutic index was increased in rodents as much as several hundred times upon administration of the drug in various liposomes. Unexpectedly, and unfortunately, there was not much interest to scale up the formulations and clinically approve them after several very encouraging studies dating back to 1978. Only now, there are several continuing studies with various anti-parasitic liposome formulations in humans. These formulations use mostly ionosphere amphotericin B and are transplanted from very successful and prolific area of liposome formulations in antifungal therapy. The best results reported so far in human therapy are probably liposomes as carriers foramphotericin B in antifungal therapies.

This is the drug of choice in dispersed fungal infections which often in parallel work together with chemotherapy, immune system, or AIDS, and is frequently fatal. Unfortunately, the drug itself ROS1 is very toxic and its dosage is limited due to its ionosphere and neurotoxicity. These toxicities are normally related with the size of the drug molecule or its complex. Obviously, liposome encapsulation inhibits the accumulation of drug in these organs and radically reduces toxicity [53]. Furthermore, often, the fungus exists in the cells of the mononuclear phagocytic system; therefore, the encapsulation results in reduced toxicity and passive targeting. These benefits, however, can be associated with any colloidal drug carrier. Certainly, similar improvements in therapy were observed with stable mixed micellar formulations and micro-emulsions [54]. Additionally, it seems that many of the early liposomal preparations were in actual fact liquid crystalline colloidal particles rather than self-closed MLV.